The CNS can be a safe space for CARs

In this issue of Blood, Frigault et al report that tisagenlecleucel, a CD19-specific chimeric antigen receptor (CAR) T-cell product, has a safety profile in a small series of patients with aggressive B-cell non-Hodgkin lymphomas (B-NHLs) and secondary central nervous system (CNS) involvement similar to that seen in patients without active CNS disease. 1 The Frigault et al study suggests that this product may benefit this previously excluded group of patients without an increased risk of neurotoxicity.